Core Viewpoint - The Ardent Health class action lawsuit alleges that the company and its executives made misleading statements regarding financial practices and liability reserves, leading to significant stock price declines after revelations of financial discrepancies [3][4]. Group 1: Class Action Details - The class action lawsuit is titled Postiwala v. Ardent Health, Inc., and it involves purchasers of Ardent Health securities from July 18, 2024, to November 12, 2025 [1]. - Investors have until March 9, 2026, to seek appointment as lead plaintiff in the lawsuit [1]. - The lawsuit claims violations of the Securities Exchange Act of 1934 by Ardent Health and its executives [1]. Group 2: Allegations Against Ardent Health - The lawsuit alleges that Ardent Health did not rely on accurate methods for determining the collectability of accounts receivable, leading to inflated financial reports [3]. - It is claimed that Ardent Health's accounts receivable framework allowed for delayed recognition of losses, resulting in materially misleading financial positions [3]. - The company allegedly lacked sufficient professional malpractice liability insurance and reserves to cover claims, particularly in the New Mexico market [3]. Group 3: Financial Impact - On November 12, 2025, Ardent Health reported a $43 million decrease in third-quarter revenue due to revised accounts receivable collectability assessments [4]. - The company also cut its 2025 EBITDA guidance by approximately 9.6%, from a range of $575 million - $615 million to $530 million - $555 million, citing industry-wide cost pressures [4]. - Following these announcements, Ardent Health's stock price fell nearly 34% [4].
Ardent Health, Inc. Investors with Significant Losses Have Opportunity to Lead the Ardent Health Class Action Lawsuit - Robbins Geller Rudman & Dowd LLP